BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) had a loss and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 0.72%.
BioCryst Pharmaceuticals, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased to $-0.22 in the quarter versus EPS of $-0.29 in the year-earlier quarter.
Revenue: Decreased 21.46% to $4.1 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: BioCryst Pharmaceuticals, Inc. reported adjusted EPS loss of $-0.22 per share. By that measure, the company missed the mean analyst estimate of $-0.16. It beat the average revenue estimate of $4.02 million.
Quoting Management:“Our team is focused on achieving near-term milestones to rebuild shareholder value. Our primary goal is to advance our potentially ground-breaking oral kallikrein inhibitors for hereditary angioedema. Phase 1 clinical trials for the lead compound, BCX4161, are scheduled to begin in the next few months and we are finalizing lead optimization for our second generation compound,” said Jon P. Stonehouse, President & Chief Executive Officer. “Furthermore, we are advancing BCX4430, a broad spectrum antiviral that could fill an important gap in the U.S. Government’s medical countermeasure stockpile. Based on BCX4430’s efficacy in treating various hemorrhagic fever viruses in animals, this compound could satisfy this important unmet need.”
Key Stats (on next page)…